2019, Number 2
Behavior of capacities and losses in the production of the Finlay Institute of Vaccines in the year 2017
Naranjo-Medina M, González-Villanueva L, Contreras-Torres DE, Gutiérrez-Quintana Y, Cepero-Cuervo ZC, Lazo-Patterson MM, Villegas-Cabrera A, Teruel-Sera JC, Chacón-Ricardo O
Language: Spanish
References: 11
Page: 55-61
PDF size: 298.96 Kb.
ABSTRACT
The analysis losses and capacities are fundamental for the managerial administration because allow to know the degree of use that is made of each resources in the organization and to optimize them. Both studies constitute an useful tool to impact in the cost and to improve the efficiency of the company. Presently work was analyzed the behavior of the capacities and losses at the Finlay Vaccine Institute in the year 2017, taking into account the plan of capacities and losses certified by BioCubaFarma for this year. An evaluation of the behavior of the use of productive capacities per months at the end of 2017 was carried out, having like base the comparison among the production plan per months, the real produced and the monthly productive capacity. Also a comparative study among the company total losses and the monthly real one for each vaccine with regard to the standard established was carried out. The results showed that in 2017 the use of productive capacities were 78.9%, impacting negatively in this aspect the constants breaks of the filled line. 80% was obtained for execution of production plan, with the biggest affectations in May, August and September due to breaks of critical systems; breaks of equipment and the affectations caused by the hurricane Irma. At the end of the analyzed year, the losses were below the certified one. However, the months of June, July August and December showed an increment above that planned. The vaccines that contribute with bigger losses were: vax-TET® with 13.7%, VA-DIFTET® with 13.0% and diTe-vax- with 11.3%, being the stage of filled of bigger losses contribution. The vaccine that systematically contributed with losses was vax-TET® vaccine, in the unidoses presentation.REFERENCES